

FORM PTO-1449
(R v. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-479-C

Serial No.

10/629,368

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:

Belardinelli

Filing Date:

7/29/03

Group:

Art Unit 1623

~~3737~~

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<i>AA1</i>	6,026,317	2/15/00	Verani			
<i>AB1</i>	6,403,567	6/11/02	Zablocki			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No
<i>AL1</i> WO 00/78778	12/28/00	PCT				
<i>AM1</i> WO 01/62979	8/30/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).


<i>AR2</i>	Xu, et al. "Coronary Vasodilation by a Short Acting, Low Affinity A2A Adenosine Receptor Agonist in Anesthetized Closed Chest Dogs: A Second Generation of Coronary Artery Pharmacologic Stressor", <i>Circulation</i> , vol. 102, no. 18, pp. 3912 (2000).

EXAMINER L. E. Crane

DATE CONSIDERED 05/19/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEHLEN
HULBERT & BERGHOFF
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60608
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-479-C	Serial No. 10/629,368
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
		(Use several sheets if necessary)			
				Applicant: Belardinelli	
				Filing Date: 7/29/03	Group: Art Unit 1623 8737

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<i>Me</i>	AA2	4,956,345	9/11/90	Miyasaka et al	_____	_____	
	AB2	4,968,697	11/6/90	Hutchison	_____	_____	
	AC2	5,070,877	12/10/91	Mohiuddin et al	_____	_____	
	AD2	5,189,027	2/23/93	Miyashita et al.	_____	_____	
	AE2	5,270,304	12/14/93	Kogi et al	_____	_____	
	AF2	5,459,254	10/17/95	Yamaguchi et al.	_____	_____	
	AG2	5,593,975	1/14/97	Cristalli	_____	_____	
	AH2	5,705,491	1/6/98	Yamada	_____	_____	
	AI2	5,770,716	6/23/98	Khan et al.	_____	_____	
	AK2	5,939,543	8/17/99	Morozumi et al.	_____	_____	
	AL2	6,214,807	4/10/01	Zablocki et al.	_____	_____	
<i>Me</i>	AM2	US2004/0127533	7/1/04	Hart et al.	_____	_____	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>Me</i>	AN2	WO 93/25677	12/13/93	PCT	_____	_____		

EXAMINER L. E. Crane	DATE CONSIDERED 05/19/2006
-----------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHLEN
 HULBERT & BERGHOFF
 300 SOUTH WACKER DRIVE
 CHICAGO, ILLINOIS 60606
 TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-479-C	Serial No. 10/629,368
			Applicant: Belardinelli	
			Filing Date: 7/29/03	Group: Art Unit 1623 3737
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<input checked="" type="checkbox"/>	AO2	WO 00/78779	12/28/00	PCT				
<input checked="" type="checkbox"/>	AP2	WO 04/011010	2/5/04	PCT				
<input checked="" type="checkbox"/>	AQ2	EP 0354 638	2/14/90	EP				
<input checked="" type="checkbox"/>	AR2	965,411	4/1/75	CA				
<input checked="" type="checkbox"/>	AS2	Hei 5[1993]-9197	1/19/93	JP				


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

<input checked="" type="checkbox"/>	AT2	Iskandrian, A, "Adenosine Myocardial Perfusion Imaging", <i>The Journal of Nuclear Medicine</i> , vol. 35, pp. 734-736 (1994).
<input checked="" type="checkbox"/>	AU2	Gao, et al., "Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists", <i>Journal of Pharmacology and Experimental Therapeutics</i> , vol. 298, pp. 209-218 (2001).
<input checked="" type="checkbox"/>	AV2	Marumoto, et al., "Synthesis and Coronary Vasodilating Activity of 2-Substituted Adenosines", <i>Chem. Pharm. Bull.</i> 23(4): 759-774 (1975).
<input checked="" type="checkbox"/>	AW2	Marumoto, et al., "Synthesis and Enzymatic Activity of Adenosine 3',5'-Cyclic Phosphate Analogs", <i>Chem. Pharm. Bull.</i> 27(4) 990-1003 (1979).
<input checked="" type="checkbox"/>	AX2	Persson, et al., "Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives", <i>Bioorganic & Medicinal Chemistry</i> , 3:1377-1382 (1995).
<input checked="" type="checkbox"/>	AY2	Mager, et al., "Molecular simulation applied to 2-(N'-alkylidenehydrazino)- and 2-(N'-aralkylidenehydrazino) adenosine A ₂ Agonists", <i>Eur J. Med. Chem.</i> 30:15-25 (1995).
<input checked="" type="checkbox"/>	AZ2	Cristalli et al., "2-Alkynyl Derivatives of Adenosine 5'-N'-ethyluronamide: Selective A ₂ Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation", <i>J. Med. Chem.</i> 37:1720-1726 (1994).
<input checked="" type="checkbox"/>	BA2	Matsuda, et al., "Nucleosides and Nucleotides. 103. 2-Alkynyladenosines: A Novel Class of Selective Adenosine A ₂ Receptor Agonists with Potent Antihypertensive Effects", <i>J. Med. Chem.</i> 35:241-252 (1992).

EXAMINER L. E. Crane	DATE CONSIDERED 05/19/2006
-----------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHLEN
 HULBERT & BERGHOFF
 300 SOUTH WACKER DRIVE
 CHICAGO, ILLINOIS 60606
 TELEPHONE (312) 913-0001



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/629,368
Filing Date	7/29/2003
First Named Inventor	Belardinelli
Art Unit	3737 1623
Examiner Name	Not Assigned
Attorney Docket Number	02-479-C

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/	AA3=	US- 2004/0064039	4-1-04	Belardinelli	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
/						

Examiner Signature	L, E. Crane	Date Considered	05/19/2006
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known	
		Application Number	10/629,368
		Filing Date	7/29/03
		First Named Inventor	Belardinelli
		Art Unit	3737 1623
		Examiner Name	Not Assigned
Sheet 2 of 2	Attorney Docket Number	02-479-C	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Inc.	AR3	Jadbabaie, et al. "Myocardial perfusion imaging with a novel selective A2A adenosine receptor agonists (CVT-3146): Important differences in radiotracer behavior, JACC, p. 443-4	
Inc.	AS3	Zhao et al. "Comparative Profile of Vasodilation by CVT-3146, a Novel A2A Receptor Agonist, & Adenosine in Conscious Dogs", Jour. of Pharm & Experimental Therapeutics, p. 182-9	
Inc.	AT3	Trochu et al. "Selective A2A Adenosine Receptor Agonist as a Coronary Vasodilator in Conscious Dogs: Potential for Use in Myocardial Perfusion Imaging, " Jour. of Cardiovasc.	

Examiner Signature	L. E. Crane <i>[Signature]</i>	Date Considered	05/19/2006
--------------------	--------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Inc. - Incomplete citation: missing bibliographic information including
volum numbers; dates of publication, etc.



PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Institute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete If Known

Application Number 10/629,368

Filing Date July 29, 2003

First Named Inventor Belardinelli

Art Unit 3737 -- 1623

Examiner Name Not Assigned

Attorney Docket Number 02-479-C

Sheet 1

of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>Pre</i>	AR4	Glover et al. "Pharmacological Stress Thallium Scintigraphy with 2- Cyclohexylmethylidenehydrazinoadenosine", Circulation, pp.1726-1732 (1996)	

Examiner
Signature

L. E. Crane

Date
Considered

05/19/2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.USCourtForms.com

10/629,368 - PTO-1449 #4

COPY FOR [] File ☒ Applicant



PTO/SB/08a (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/629,368
Filing Date	July 29, 2003
First Named Inventor	Belardinelli
Art Unit	3737 — 1623
Examiner Name	Not Assigned
Attorney Docket Number	02-479-C

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
	AL 5	WO 98/57651	12-12-98	Martin et al.		
	AM 5	WO 98/52611	11-26-98	Ozaki et al.		X
	AN 5	JP S48-26038	8-3-73	Honjoki		X

Examiner
Signature

L. E. Crane

Date
Considered

05/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.USCourtForms.com

10/629,368 - PTO-1449 #5

COPY FOR [] File [X] Applicant